Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT02598349 | Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | recruiting | Phase 2 | 60 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT04175912 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04396821 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 150 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | active not recruiting | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04605913 | Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC | active not recruiting | Phase 1 / Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04751370 | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05322590 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma(ASIST) | active not recruiting | Phase 1 / Phase 2 | 195 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05611034 | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | recruiting | Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05731271 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 111 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05803382 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05927142 | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy(DURIPANC) | active not recruiting | Phase 1 / Phase 2 | 43 | Joachim Aerts, MD PhDOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06046794 | Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients(GemSign-01) | recruiting | N/A | 100 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06093425 | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma | not yet recruiting | Phase 3 | 820 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06605664 | Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(PRISM-1) | active not recruiting | Phase 3 | 610 | Arcus Biosciences, Inc.INDUSTRY | 13 | Sep 29, 2026 | clinicaltrials |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors(STELLAR-311) | recruiting | Phase 2 / Phase 3 | 440 | ExelixisINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT07127874 | A Study of PHN-012 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Pheon TherapeuticsINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT07212491 | Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma | enrolling by invitation | — | 450 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07265674 | A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer(Beacon-BTC) | recruiting | Phase 3 | 480 | J-Pharma Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07328516 | Natural History Study of Early Life Exposures in Agriculture (ELEA) | enrolling by invitation | — | 64,277 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07346586 | Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery | recruiting | N/A | 1,545 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07529808 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 164 | BigHat Biosciences, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07551596 | Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07578571 | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | recruiting | Phase 1 | 175 | Immunome, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07603375 | Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma(TNT Esophagus) | recruiting | Phase 2 | 60 | Duke UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer(TARGET-D 203) | recruiting | Phase 2 | 150 | Verastem, Inc.INDUSTRY | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07766187 | Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma(CODAH) | not yet recruiting | Phase 2 | 12 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845617 | Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma | recruiting | — | 10 | AdventHealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845877 | An Intervention to Reduce Sedentary Behavior and Promote Physical Activity in Colorectal Cancer Chemotherapy | not yet recruiting | N/A | 40 | Yonsei UniversityOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07846046 | Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer(ENSURE) | not yet recruiting | N/A | 246 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846267 | Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma(CASTLE-ZS-05) | not yet recruiting | Phase 2 | 56 | Fudan UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847216 | Multicenter Prospective Study Protocol for Validating Surgical Quality Standards in D3 Lymphadenectomy for Oncological Right Hemicolectomy(D3L) | not yet recruiting | — | 120 | Fundació d'investigació Sanitària de les Illes BalearsOTHER_GOV | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07847671 | Fecal Microbiota Transplantation With QL1706 Plus Bevacizumab for Advanced HCC | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847710 | Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial(H-FROG) | recruiting | Phase 2 | 81 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | recruiting | Phase 2 | 50 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00001276 | Diagnosing and Treating Low Blood Sugar Levels | recruiting | — | 1,500 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00034216 | Collection of Blood From Patients With Cancer | recruiting | — | 1,750 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00068003 | Harvesting Cells for Experimental Cancer Treatments | enrolling by invitation | — | 7,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02595957 | Genomic Services Research Program | recruiting | — | 5,000 | National Human Genome Research Institute (NHGRI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
Data updated 13 hours agoSource updated Sep 29, 2026source: clinicaltrials